Testing a new drug target for migraine relief
Part of Brain & nervous system, Pain clinical trials.
This trial tests a substance that activates adrenomedullin receptors, which may be a new way to treat migraines. It may help people who have migraines without aura and aren't on preventive migraine medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have had migraines without aura for at least 1 year.
- You currently have 1 to 5 migraine attacks per month.
- You have not taken any preventive migraine medication in the last 30 days.
- You have never used treatments that target CGRP (like certain antibody injections or pills).
- You are not pregnant, breastfeeding, or planning to become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a natural substance called amylin can trigger a migraine attack in people who get migraine without aura. If you have 1 to 5 migraine days a month and are otherwise healthy, you may be able to help researchers understand what causes migraines.
This study tests new ways to monitor how well preventive migraine treatments are working. It is for people with chronic migraine who may be starting or already using preventive medications.
This trial tests a new medicine, MEDI0618, against a placebo for people with episodic migraine. The goal is to see if MEDI0618 is safe and effective at reducing migraine days.
This study tests a new inhaled powder form of a migraine medication called dihydroergotamine (DHE) to see if it safely and effectively stops migraine attacks. If you have frequent migraines, this trial might offer you a new treatment option to try.
This study tests a new medication called NB001 to help stop migraine headaches when they happen. Researchers want to see if it works better than current treatments for people who have frequent migraines.
This study tests whether a substance called CGRP (a protein linked to migraines) can safely trigger a migraine with aura in people who already have this condition. You'll receive an infusion and be monitored to see how your body responds.
Hear when a new Migraine trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.